Clinical trial
Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing…
NCT00477880 · Vanderbilt University, Other · Completed
Key facts
| NCT number | NCT00477880 |
|---|---|
| Title | Cetuximab in Treating Patients With Ménétrier Disease at High Risk of Developing Stomach Cancer |
| Official title | Treatment of Ménétrier's Disease With EGF Receptor Blockade |
| Lead sponsor | Vanderbilt University, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Gastric Cancer, Precancerous Condition |
| Intervention type | Biological |
| Interventions | Cetuximab |
| Enrollment | 9 |
| Start date | Apr 1, 2001 |
| Primary completion | Sep 1, 2010 |
| Completion | Sep 1, 2010 |
| First posted | May 24, 2007 |
| Last update posted | Jan 10, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: